CUREVAC NV (CVAC) Stock Overview
NASDAQ:CVAC - NL0015436031 - Common Stock
CVAC Key Statistics, Chart & Performance
The current stock price of CVAC is 5.37 USD. In the past month the price decreased by -0.74%. In the past year, price increased by 71.02%.
CVAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About CVAC
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 904
Phone: 49707198830
CUREVAC NV / CVAC FAQ
What is the stock price of CUREVAC NV today?
The current stock price of CVAC is 5.37 USD.
What is the ticker symbol for CUREVAC NV stock?
The exchange symbol of CUREVAC NV is CVAC and it is listed on the Nasdaq exchange.
On which exchange is CVAC stock listed?
CVAC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CUREVAC NV stock?
13 analysts have analysed CVAC and the average price target is 4.92 USD. This implies a price decrease of -8.45% is expected in the next year compared to the current price of 5.37. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CUREVAC NV worth?
CUREVAC NV (CVAC) has a market capitalization of 1.21B USD. This makes CVAC a Small Cap stock.
How many employees does CUREVAC NV have?
CUREVAC NV (CVAC) currently has 904 employees.
What are the support and resistance levels for CUREVAC NV (CVAC) stock?
CUREVAC NV (CVAC) has a support level at 5.36 and a resistance level at 5.41. Check the full technical report for a detailed analysis of CVAC support and resistance levels.
Is CUREVAC NV (CVAC) expected to grow?
The Revenue of CUREVAC NV (CVAC) is expected to decline by -84.64% in the next year. Check the estimates tab for more information on the CVAC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CUREVAC NV (CVAC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CVAC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CVAC, evaluating the profitability, health, valuation and growth aspects
- CUREVAC NV (CVAC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CUREVAC NV (CVAC) Sales and EPS estimates to see what analysts future expectations are.
- CUREVAC NV (CVAC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CUREVAC NV (CVAC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CUREVAC NV (CVAC) Stock Chart to make your own analysis
- CUREVAC NV (CVAC) Latest news and press-releases to stay up to date.
Does CUREVAC NV (CVAC) stock pay dividends?
CVAC does not pay a dividend.
When does CUREVAC NV (CVAC) report earnings?
CUREVAC NV (CVAC) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of CUREVAC NV (CVAC)?
The PE ratio for CUREVAC NV (CVAC) is 5.32. This is based on the reported non-GAAP earnings per share of 1.01 and the current share price of 5.37 USD. Check the full fundamental report for a full analysis of the valuation metrics for CVAC.
What is the Short Interest ratio of CUREVAC NV (CVAC) stock?
The outstanding short interest for CUREVAC NV (CVAC) is 0.77% of its float. Check the ownership tab for more information on the CVAC short interest.
CVAC Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is one of the better performing stocks in the market, outperforming 91.12% of all stocks.
CVAC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CVAC. While CVAC has a great health rating, its profitability is only average at the moment.
CVAC Financial Highlights
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 1.01. The EPS increased by 170.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.93% | ||
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| Debt/Equity | 0.05 |
CVAC Forecast & Estimates
13 analysts have analysed CVAC and the average price target is 4.92 USD. This implies a price decrease of -8.45% is expected in the next year compared to the current price of 5.37.
For the next year, analysts expect an EPS growth of -165.87% and a revenue growth -84.64% for CVAC